DKK1 and Miyoshi myopathy: BHQ880, a DKK1-neutralizing antibody, can increase osteoblast differentiation, neutralize the negative effect of MM cells on osteoblastogenesis, reduce IL-6 secretion, upregulate β-catenin levels, and downregulate nuclear factor-κB (NF-κB) activity in BMSCs in in vitro study [70,79].